Skip to main content
Terug
PHMMF logo

Pharma Mar, S.A.

Datakwaliteit: 100%
Overbought
PHMMF
OTC Healthcare Biotechnology
€ 92,19
▲ € 3,47 (3,91%)
Marktkapitalisatie: 1,60B
Dagbereik
€ 92,19 € 92,19
52-Weeksbereik
€ 80,91 € 110,40
Volume
3.750
50D / 200D Gem.
€ 87,88 / € 92,53
Vorige Slotkoers
€ 92,19

Koershistorie

Financiële Trends

Sectorvergelijking

vs Healthcare sector mediaan (626 peers)

Metriek Aandeel Sector Mediaan
P/E 21,3 0,4
P/B 6,3 2,9
ROE % 32,6 3,8
Net Margin % 33,9 3,9
Rev Growth 5Y % -0,9 10,0
D/E 0,2 0,2

Belangrijkste Punten

Revenue declined -0,94% annually over 5 years
Earnings grew 186,92% over the past year
ROE of 32,58% indicates high profitability
Net margin of 33,87% shows strong profitability
Debt/Equity of 0,20 — conservative balance sheet
Generating 43,73M in free cash flow

Groei

Revenue Growth (5Y)
-0,94%
Revenue (1Y)26,57%
Earnings (1Y)186,92%
FCF Growth (3Y)N/A

Kwaliteit

Return on Equity
32,58%
ROIC9,99%
Net Margin33,87%
Op. Margin18,19%

Veiligheid

Debt / Equity
0,20
Current Ratio3,02
Interest Coverage37,85

Waardering

P/E Ratio
21,31
P/B Ratio6,34
EV/EBITDA40,48
Dividend Yield0,01%

All Fundamental Metrics

Growth
Revenue Growth (1Y) 26,57% Revenue Growth (3Y) 18,29%
Earnings Growth (1Y) 186,92% Earnings Growth (3Y) 711,95%
Revenue Growth (5Y) -0,94% Earnings Growth (5Y) -5,21%
Profitability
Revenue (TTM) 221,31M Net Income (TTM) 74,96M
ROE 32,58% ROA 18,98%
Gross Margin 94,46% Operating Margin 18,19%
Net Margin 33,87% Free Cash Flow (TTM) 43,73M
ROIC 9,99% FCF Growth (3Y) N/A
Safety
Debt / Equity 0,20 Current Ratio 3,02
Interest Coverage 37,85 Dividend Yield 0,01%
Valuation
P/E Ratio 21,31 P/B Ratio 6,34
P/S Ratio 7,22 PEG Ratio 0,09
EV/EBITDA 40,48 Dividend Yield 0,01%
Market Cap 1,60B Enterprise Value 1,63B

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 221,31M 174,86M 158,15M 196,34M 229,83M
Net Income 74,96M 26,13M 1,14M 49,36M 92,86M
EPS (Diluted) 4,36 1,49 0,06 2,73 5,13
Gross Profit 209,05M 166,67M 148,54M 182,70M 213,39M
Operating Income 40,26M 6,47M -3,83M 44,07M 92,45M

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 394,93M 349,64M 340,52M 393,26M 368,39M
Total Liabilities 142,48M 141,29M 147,08M 170,30M 190,47M
Shareholders' Equity 251,74M 208,36M 193,44M 222,96M 177,92M
Total Debt 50,53M 51,08M 43,67M 42,63M 49,33M
Cash & Equivalents 17,81M 63,24M 60,02M 149,81M 113,35M
Current Assets 283,31M 250,25M 252,60M 275,18M 295,23M
Current Liabilities 93,84M 82,69M 95,89M 97,32M 86,35M

Strategiescores

This stock passed the criteria for 1 strategy

Score = fit strength (0–100)
Rank = position among all matches
#58 of 326
67

Recente Activiteit

Ingestapt Growth at a Reasonable Price (Peter Lynch)
Mar 24, 2026